Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Ornella Garrone et al.|The Lancet|2015Cited by 201
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Francesca Poggio et al.|The Lancet Oncology|2022Cited by 50
Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone et al.|International Journal of Cancer|2019Cited by 20
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lucia Del Mastro, Lorenzo Gerratana et al.|npj Breast Cancer|2021Cited by 9
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialFrancesca Poggio, Lucia Del Mastro, Eva Blondeaux et al.|ESMO Open|2024Cited by 5